Dr. Denlinger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-7526
Education & Training
- Ohio State University HospitalResidency, Internal Medicine, 2015 - 2018
- Ohio University Heritage College of Osteopathic Medicine in AthensClass of 2015
Certifications & Licensure
- OH State License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Roles: Contact
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Start of enrollment: 2024 Jan 29
Roles: Sponsor-Investigator
Publications & Presentations
PubMed
- 1 citationsPostinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.Nathan Denlinger, No-Joon Song, Xiaoli Zhang, Hyeongseon Jeon, Chelsea Peterson
Blood Advances. 2024-06-25 - 4 citationsA novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh
Experimental Hematology & Oncology. 2023-09-22 - 23 citationsPeri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen
Blood Advances. 2023-06-27
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: